DMAC net incomeQ2 2026-$10.14M
DMAC net income was -$10.14M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$7.70M a year earlier. For the full fiscal 2025 it was -$32.77M, compared with -$24.44M in fiscal 2024.
DiaMedica Therapeutics Inc. (DMAC) financials
For the twelve months ended Jun 30, 2026, DiaMedica Therapeutics Inc. reported -$37.54M of net income.
- Net income, TTM
- -$37.54M
- Free cash flow, TTM
- -$31.54M
- Cash
- $5.13M
- Market cap
- $520.4M
FY2017FY2025
FY2017FY2025
DMAC revenue and earnings growth
DMAC free cash flowQ2 2026-$8.12M
DMAC free cash flow was -$8.12M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$7.60M a year earlier. For the full fiscal 2025 it was -$29.10M, compared with -$22.10M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $500.0K | - |
| Research and development | $24.61M | $19.06M | $13.11M | $7.84M | $8.77M | $8.21M | $7.90M | $4.52M | $3.21M |
| Selling, general and admin | $9.78M | $7.62M | $8.16M | $6.16M | $4.88M | $4.49M | $3.69M | $2.74M | $1.31M |
| Operating income | -$34.40M | -$26.68M | -$21.27M | -$14.00M | -$13.65M | -$12.70M | -$11.59M | -$6.76M | -$4.52M |
| Pre-tax income | -$32.74M | -$24.41M | -$19.34M | -$13.65M | -$13.56M | -$12.27M | -$10.62M | -$5.65M | -$4.26M |
| Income tax | $28.0K | $30.0K | $43.0K | $28.0K | $28.0K | $27.0K | $31.0K | $80.0K | - |
| Net income | -$32.77M | -$24.44M | -$19.38M | -$13.68M | -$13.59M | -$12.29M | -$10.65M | -$5.73M | -$4.26M |
| EPS, basic | -$0.70 | -$0.60 | -$0.60 | -$0.52 | -$0.65 | -$0.78 | -$0.89 | -$0.74 | -$0.72 |
| EPS, diluted | - | - | - | - | -$0.65 | -$0.78 | -$0.89 | -$0.74 | -$0.72 |
| Diluted shares | - | - | - | - | 20.8M | 15.7M | 12.0M | 7.7M | 5.9M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $15.65M | $3.02M | $4.54M | $4.73M | $4.71M | $7.41M | $3.88M | $16.82M | $1.35M |
| Short-term investments | $44.24M | $41.12M | $48.35M | $28.77M | $40.41M | $20.10M | $4.00M | - | - |
| Receivables | $258.0K | $236.0K | $369.0K | $82.0K | $130.0K | $340.0K | $823.0K | $780.0K | $80.0K |
| Current assets | $60.63M | $44.61M | $53.67M | $33.84M | $45.44M | $27.92M | $8.84M | $17.97M | $1.49M |
| Total assets | $61.37M | $46.34M | $54.16M | $34.40M | $45.55M | $28.09M | $9.05M | $18.34M | $1.80M |
| Current liabilities | $5.13M | $5.39M | $2.79M | $2.17M | $1.52M | $2.03M | $1.32M | $1.30M | $1.00M |
| Shareholders' equity | $56.11M | $40.72M | $51.06M | $31.83M | $44.02M | $26.01M | $7.62M | $17.02M | $799.0K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.06M | -$22.08M | -$18.73M | -$11.51M | -$12.25M | -$9.19M | -$9.10M | -$5.70M | -$3.90M |
| Capital expenditures | $40.0K | $25.0K | $24.0K | $81.0K | $22.0K | $47.0K | $2.0K | $50.0K | $22.0K |
| Free cash flow | -$29.10M | -$22.10M | -$18.75M | -$11.59M | -$12.27M | -$9.23M | -$9.10M | -$5.75M | -$3.92M |
| Investing cash flow | -$2.19M | $8.56M | -$18.30M | $11.54M | -$20.54M | -$16.13M | -$3.91M | -$50.0K | -$22.0K |
| Financing cash flow | $43.88M | $11.99M | $36.84M | -$6.0K | $30.09M | $28.84M | $70.0K | $21.22M | $3.54M |
| Stock-based compensation | $3.85M | $2.08M | $1.68M | $1.50M | $1.56M | $1.84M | $1.16M | $620.0K | $409.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | - | - | - | - | - | - | - | -1352.2% | - |
| Net margin | - | - | - | - | - | - | - | -1146.8% | - |
| Free cash flow margin | - | - | - | - | - | - | - | -1149.2% | - |
| Return on equity | -58.4% | -60.0% | -38.0% | -43.0% | -30.9% | -47.3% | -139.8% | -33.7% | -533.2% |
| Return on assets | -53.4% | -52.7% | -35.8% | -39.8% | -29.8% | -43.8% | -117.6% | -31.3% | -236.4% |
| Current ratio | 11.81 | 8.28 | 19.27 | 15.61 | 29.82 | 13.77 | 6.70 | 13.87 | 1.49 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $8.15M | $7.99M | $6.70M | $6.44M | $5.82M | $5.66M | $6.47M | $4.98M | $3.93M | $3.68M | $3.68M | $3.27M |
| Selling, general and admin | $2.35M | $2.50M | $2.51M | $2.60M | $2.19M | $2.49M | $1.95M | $1.90M | $1.71M | $2.06M | $2.17M | $1.89M |
| Operating income | -$10.50M | -$10.48M | -$9.21M | -$9.03M | -$8.01M | -$8.14M | -$8.42M | -$6.88M | -$5.64M | -$5.74M | -$5.85M | -$5.16M |
| Pre-tax income | -$10.13M | -$10.04M | -$8.73M | -$8.61M | -$7.69M | -$7.70M | -$7.89M | -$6.27M | -$5.11M | -$5.14M | -$5.14M | -$4.46M |
| Income tax | $7.0K | $7.0K | $10.0K | $6.0K | $6.0K | $6.0K | $9.0K | $7.0K | $7.0K | $7.0K | $22.0K | $7.0K |
| Net income | -$10.14M | -$10.04M | -$8.74M | -$8.62M | -$7.70M | -$7.71M | -$7.90M | -$6.27M | -$5.12M | -$5.15M | -$5.16M | -$4.47M |
| EPS, basic | -$0.19 | -$0.19 | - | -$0.17 | -$0.18 | -$0.18 | - | -$0.15 | -$0.13 | -$0.14 | - | -$0.12 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.13M | $4.87M | $15.65M | $3.33M | $4.11M | $2.59M | $3.02M | $4.13M | $14.07M | $2.10M | $4.54M | $2.23M |
| Short-term investments | $38.38M | $46.46M | $44.24M | $51.99M | $25.93M | $33.73M | $41.12M | $46.06M | $39.99M | $44.42M | $48.35M | $44.23M |
| Receivables | $244.0K | $301.0K | $258.0K | $260.0K | $161.0K | $253.0K | $236.0K | $290.0K | $391.0K | $399.0K | $369.0K | $310.0K |
| Current assets | $44.31M | $52.36M | $60.63M | $56.22M | $31.08M | $37.42M | $44.61M | $50.77M | $55.01M | $47.48M | $53.67M | $47.89M |
| Total assets | $45.00M | $53.08M | $61.37M | $57.05M | $31.47M | $38.83M | $46.34M | $52.52M | $56.79M | $49.26M | $54.16M | $58.14M |
| Current liabilities | $6.59M | $5.75M | $5.13M | $5.27M | $4.12M | $4.67M | $5.39M | $4.30M | $3.09M | $2.62M | $2.79M | $2.17M |
| Shareholders' equity | $38.34M | $47.23M | $56.11M | $51.62M | $27.17M | $33.95M | $40.72M | $47.96M | $53.41M | $46.35M | $51.06M | $55.63M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.11M | -$9.08M | -$7.76M | -$6.55M | -$7.60M | -$7.15M | -$6.43M | -$4.47M | -$4.52M | -$6.65M | -$3.81M | -$4.80M |
| Capital expenditures | $3.0K | $8.0K | $6.0K | $16.0K | $6.0K | $12.0K | $7.0K | $9.0K | $0 | $9.0K | $3.0K | $10.0K |
| Free cash flow | -$8.12M | -$9.09M | -$7.77M | -$6.57M | -$7.60M | -$7.16M | -$6.44M | -$4.48M | -$4.52M | -$6.66M | -$3.81M | -$4.81M |
| Investing cash flow | $8.24M | -$2.11M | $8.00M | -$25.77M | $8.96M | $6.62M | $5.21M | -$5.58M | $4.74M | $4.21M | $6.12M | $1.20M |
| Financing cash flow | $132.0K | $417.0K | $12.09M | $31.53M | $161.0K | $91.0K | $120.0K | $123.0K | $11.75M | -$1.0K | -$1.0K | -$6.0K |
| Stock-based compensation | $1.12M | $822.0K | $1.19M | $1.02M | $771.0K | $867.0K | $589.0K | $565.0K | $443.0K | $488.0K | $456.0K | $425.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 6.72 | 9.11 | 11.81 | 10.67 | 7.55 | 8.02 | 8.28 | 11.81 | 17.82 | 18.14 | 19.27 | 22.07 |
Source: XBRL data DiaMedica Therapeutics Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
DMAC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| DMAC | - | - | -$37.54M | - | $520.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
DMAC FAQ
5 questionsIs DMAC profitable?
No. DiaMedica Therapeutics Inc. reported a net loss of $37.54M for the twelve months ended Jun 30, 2026.How much cash and debt does DMAC have?
DiaMedica Therapeutics Inc. reported $5.13M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is DMAC free cash flow?
DiaMedica Therapeutics Inc. generated -$31.54M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$31.51M less capital expenditures.When did DMAC last report financial results?
The latest statements here come from DiaMedica Therapeutics Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.Where does this DMAC financial data come from?
Quantisnow builds these statements from the structured XBRL data DiaMedica Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.